ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2500

Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients

Jacob Sode1,2,3, Ulla Vogel4, Steffen Bank5,6, Paal Skytt Andersen7, Merete Lund Hetland8,9, Henning Locht3, Niels H. H. Heegaard10,11 and Vibeke Andersen1,5,12,13, 1Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, 2Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, 3Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, 4National Research Centre for the Working Environment, Copenhagen, Denmark, 5Medical Department, Viborg Regional Hospital, Viborg, Denmark, 6Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, 7Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 9Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 10Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 11Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark, 12Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, 13Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, inflammasome activation, interferons, rheumatoid arthritis (RA) and toll-like receptors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis Patients

Background/Purpose:

In a recent study (paper in press) of Danish rheumatoid arthritis (RA) patients we found single nucleotide polymorphisms (SNPs) in the NLRP3 and interferon-γ genes to be associated with response to tumor necrosis factor a inhibitors (anti-TNF). The aim of this study was to extend and corroborate these associations by analyzing a new set of functional polymorphisms in the NLRP3-inflammasome and interferon-γ pathways in RA patients treated with anti-TNF.

Methods:

Twenty-three functional single nucleotide polymorphisms (SNPs) in 14 genes involved in the inflammasome and interferon-gamma pathways were assessed in 538 anti-TNF naive Danish RA patients. Prospectively collected clinical data including functional status (HAQ), patient global score, smoking status, tender and swollen joint counts, treatments, rheumatoid factor (RF) status and C-reative protein (CRP) were obtained from the DANBIO registry. Multivariable logistic regression analyses adjusting for sex, age, HAQ, CRP, baseline disease-modifying anti-rheumatic drugs and RF status were performed to test associations between genotypes and EULAR response—good vs. moderate/none and good/moderate vs. none—at 3–6 months follow-up. ACR50 response was also analyzed to enable comparison with other studies. Subgroup analysis was performed for patients positive for RF (N=407).

Results:

Polymorphisms in IL12B (rs6887695), TLR1 (rs4833095) and TLR5 (rs5744174) were significantly (p<0.05) associated with EULAR response (Table 1). TLR1 rs4833095 was also associated with ACR50 response. None of the associations reached significance when corrected for multiple testing by false discovery rate adjustment.

TLR5 rs5744174 variant C allele is associated with an improved anti-TNF response and maps 71 bp from another polymorphism (no linkage data exists) previously found to be associated with RA anti-TNF response in a Dutch cohort (1) and it has been associated with higher PBMC IFN-γ secretion and altered CCL20 production. TLR1 rs4833095 has been associated with high PBMC TLR1 expression.

Subgroup associations were found for seropositive RA in CARD8 (rs2043211), IL18 (rs187238) and TLR1 (rs4833095) (data not shown) but due to low power these results are preliminary.

Conclusion:

Our results confirm association between a TLR5 locus and EULAR response to anti-TNF treatment. Previous studies suggest that this polymorphism is functional and associated with a phenotype with altered cytokine expression. The associations found for other polymorphisms need validation in a new cohort.


Table 1. Associations between gene variants and anti-TNF treatment response.

ACR50 response

EULAR response

yes vs. no

G vs. M/N

G/M vs. N

Gene (SNP)

Genotype

N

Adj. OR (95% CI), P-value

Adj. OR (95% CI), P-value

Adj. OR (95% CI), P-value

TLR1

TT

312

rs4833095

TC

178

1.38 (0.92-2.05), 0.118

1.02 (0.70-1.50), 0.903

1.11 (0.73-1.68), 0.631

CC

21

3.43 (1.38-8.52), 0.008**

3.11 (1.18-8.19), 0.022*

1.34 (0.47-3.81), 0.584

TC/CC

199

1.52 (1.04-2.24), 0.031*

1.15 (0.79-1.66), 0.462

1.13 (0.76-1.69), 0.555

TLR5

TT

170

rs5744174

TC

234

1.27 (0.82-1.96), 0.281

1.53 (1.01-2.33), 0.044*

1.17 (0.76-1.81), 0.470

CC

107

1.40 (0.83-2.36), 0.206

1.89 (1.14-3.13), 0.014*

1.38 (0.80-2.38), 0.247

TC/CC

341

1.31 (0.87-1.97), 0.192

1.64 (1.11-2.42), 0.013*

1.23 (0.82-1.85), 0.310

IL12B

GG

241

rs6887695

GC

224

1.14 (0.76-1.69), 0.529

0.82 (0.56-1.19), 0.291

0.63 (0.42-0.95), 0.027*

CC

51

1.44 (0.76-2.73), 0.267

0.87 (0.46-1.64), 0.664

1.68 (0.77-3.67), 0.197

GC/CC

275

1.19 (0.82-1.73), 0.369

0.83 (0.58-1.18), 0.294

0.74 (0.50-1.09), 0.129

G/M/N: good/moderate/none response

(1)   Coenen MJ et al. PLoS One 2010; 5(12):e14326.


Disclosure:

J. Sode,
None;

U. Vogel,
None;

S. Bank,
None;

P. S. Andersen,
None;

M. L. Hetland,
None;

H. Locht,
None;

N. H. H. Heegaard,
None;

V. Andersen,

MSD/Merck,

5,

Janssen Pharmaceutica Product, L.P.,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-variation-in-the-tlr5-locus-is-associated-with-anti-tnf-response-among-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology